In preclinical models (20) and clinical studies (21) in a diverse panel of cancers, enhanced efficiency of FAK inhibitors (FAKi) was observed in tumors harboring reduced Merlin levels; however, a correlation between Merlin expression and FAKi sensitivity in PDAC remains to be assessed. This evidence concerns the gene NF2 and cancer.